How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about vorasidenib

Marketing authorisation indication

2.1

Vorasidenib (Voranigo, Servier Laboratories) is indicated for 'the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention'.

Price

2.3

The list price of a 30-tablet pack of vorasidenib is £15,000 for 40-mg tablets and £7,500 for 10-mg tablets (excluding VAT; company submission).

2.4

The company has a commercial arrangement. This makes vorasidenib available to the NHS with a discount and it would have also applied to this indication if vorasidenib had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Servier Laboratories will be included here when guidance is published.